Evidence map›Paper›PMID 38496628›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity.

Alex L Roederer, Yi Cao, Kerri St Denis, Maegan L Sheehan, Chia Jung Li, Evan C Lam, David J Gregory, Mark C Poznansky, A John Iafrate, David H Canaday and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Alex L RoedererRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Yi CaoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Kerri St DenisRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Maegan L SheehanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Chia Jung LiRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Evan C LamRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
David J GregoryVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, 02129, USA.
Mark C PoznanskyVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, 02129, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
David H CanadayCase Western Reserve University School of Medicine, Cleveland, OH.
Stefan GravensteinCenter of Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island.
Wilfredo F Garcia-BeltranRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Alejandro B BalazsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0002-1767-3944
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USGeriatric Research Education and Clinical Center · USProvidence College · US

Funding

Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Eliminating the Immunogenicity of AAV Vectored HIV Antibody DeliveryR01AI174276 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Alejandro Benjamin Balazs · 2024 to 2026
$2.5M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
NIAID NIH HHS R01 AI174276NIAID NIH HHS R01 AI174875NIDA NIH HHS DP2 DA040254
6 · The paper itself

Abstract

Since the COVID-19 pandemic began in 2020, viral sequencing has documented 131 individual mutations in the viral spike protein across 48 named variants. To determine the ability of vaccine-mediated humoral immunity to keep pace with continued SARS-CoV-2 evolution, we assessed the neutralization potency of sera from 76 vaccine recipients collected after 2 to 6 immunizations against a comprehensive panel of mutations observed during the pandemic. Remarkably, while many individual mutations that emerged between 2020 and 2022 exhibit escape from sera following primary vaccination, few escape boosted sera. However, progressive loss of neutralization was observed across newer variants, irrespective of vaccine doses. Importantly, an updated XBB.1.5 booster significantly increased titers against newer variants but not JN.1. These findings demonstrate that seasonal boosters improve titers against contemporaneous strains, but novel variants continue to evade updated mRNA vaccines, demonstrating the need for novel approaches to adequately control SARS-CoV-2 transmission.

Indexed as

breadthCOVID-19infectivityJN.1neutralizing antibodiesSARS-CoV-2spikevaccinationvariantsXBB.1.5 Booster

Identifiers

PMID38496628
PMCPMC10942518
OpenAlexW4392543732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.